News

Organ involvement and outcomes among people with systemic sclerosis (SSc) are strongly associated with seven specific self-reactive antibodies, a French study has found. Among their findings, researchers identified antibodies that targets RNA polymerase III as strongly associated with scleroderma renal crisis, a rare and severe manifestation of SSc marked…

Zura Bio has launched a Phase 2 trial to evaluate the safety and efficacy of tibulizumab, its experimental dual pathway antibody to treat systemic sclerosis (SSc). The TibuSURE trial is expected to enroll as many as 80 adults with early diffuse cutaneous SSc. They will receive tibulizumab…

Reduction in skin thickness may indicate better lung health and survival outcomes in people with diffuse cutaneous systemic sclerosis (dcSSc), according to an analysis of patients from the European Scleroderma Trials and Research (EUSTAR) registry. “Skin regressive patients have a lower probability of lung progression, better survival,” the investigators…

Interstitial lung disease (ILD), a condition in which scarring damages lung tissue and makes breathing difficult, may appear several years after other symptoms of scleroderma (SSc) start, a study reported. Late-onset ILD in SSc was similar lung in severity and progression to the early-onset presentation. “Surveillance for incident…

Fatigue levels in people with scleroderma, also known as systemic sclerosis or SSc, are tied to several social, demographic, lifestyle, and disease-related factors, according to a study by a multinational team of researchers. Smoking, higher body mass index (BMI) —…

Soquelitinib, Corvus Pharmaceuticals’ immune-modulating investigational oral treatment for autoimmune diseases and certain cancers, reduced the signs and symptoms of lung disease caused by systemic sclerosis (SSc), according to new preclinical data. Designed to selectively block ITK, an enzyme predominantly found in immune T-cells, soquelitinib suppresses Th2 cells —…

Cells derived from people with systemic sclerosis (SSc) had widespread DNA mutations compared with healthy cells, which may explain the higher risk of cancer in this patient population, according to a study. Changes included mutational patterns found solely in the genomes of certain cancers, as well as changes in…

The specific self-reactive antibodies (autoantibodies) of people with systemic sclerosis (SSc) overlap syndrome — a condition in which SSc patients have clinical signs and autoantibodies related to other connective tissue diseases — are tied to organ damage and SSc prognosis, according to a single-center study in China. Patients with…

The annual Cool Comedy, Hot Cuisine event, a star-studded fundraiser that benefits the Scleroderma Research Foundation (SRF), brought in more than $1.3 million for scleroderma research and educational outreach. Actor and comedian Jeff Ross, and Grammy Award-winning musician John Mayer were honored with the Bob Saget Legacy Award to…

CAL101, a therapy candidate for fibrosis (scarring) in scleroderma and related disorders, was found to be safe and well tolerated in a Phase 1 clinical trial, according to new data from the study. Developed by Calluna Pharma, CAL101 is a first-in-class antibody that targets S100A4, a protein previously…